Get the latest NAV of Nippon India Pharma Fund - Growth. View historical returns compared to its benchmark and category average. Know which stocks and sectors the fund is investing in. Get an estimate of returns from the SIP and lump sum returns calculator. View detailed holding analysis and peer comparison. Get INDmoney ranking of the fund.
₹517.91
▲1.1%1D
NAV as on 27 Jun 2025
20.61%/per year
Since Inception
▲▼
Fund returns vs Benchmark returns vs Category Average returns as on (27-Jun-25)
The fund has outperformed the benchmark (Nifty 500) over 1Y, 3Y, but underperformed over 5Y.
Calculate SIP and lumpsum returns based on historical performance
Total Investment
0
Profit
Total Corpus
0
See fund asset allocation details as on (14-Jun-25)
Fund Distribution
as on (14-Jun-25)
Equity 98.6%
Debt & Cash 1.4%
See fund sector allocation details as on (14-Jun-25)
Sector Allocation
Equity 98.6%
Debt & Cash 1.4%
Top Sector in May was Health
Health
100%
Health
100%
as on (31-May-25)
Equity
Get key fund statistics, minimum investment details, AUM, expense ratio, exit load, and tax treatment.
Expense ratio | 1.8% |
Benchmark | BSE Healthcare TR INR |
AUM | ₹8352 Cr |
Inception Date | 5 June, 2004 |
Min Lumpsum/SIP | ₹5000/₹100 |
Exit Load | 1.0% |
Lock In | No Lock-in |
TurnOver | 16.09% |
STCG | Selling mutual fund before 1 year, returns taxed at 20%. |
LTCG | After 1 year, 12.5% tax on returns over ₹1.25 lakh/year. |
Risk | Very High Risk |
Nippon India Pharma Fund - Growth is an equity fund. This fund was started on 5 June, 2004. The fund is managed by Kinjal Desai, Sailesh Raj Bhan. The fund could potentially beat inflation in the long-run.
Nippon India Pharma Fund - Growth has given a CAGR return of 20.61% since inception. Over the last 1, 3 and 5 years the fund has given a CAGR return of 16.99%, 25.60% and 22.07% respectively.
Nippon India Pharma Fund - Growth has allocated its funds majorly in Cash Equivalent, Health. Its top holdings are Sun Pharmaceuticals Industries Ltd, Divi's Laboratories Ltd, Lupin Ltd, Cipla Ltd, Dr Reddy's Laboratories Ltd
As it is a sector - healthcare mutual fund the taxation is as follows:For short term (less than a year) capital gains will be taxed at 20%For long term (more than 1 year) capital gains will be taxed at 12.5% without indexation benefitDividends will always be taxed at slab rate. Long term gains upto Rs 1 lakh are exempt capital gains tax.
The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies.
Minimum investment for lump sum payment is INR 5000.00 and for SIP is INR 100.00. Nippon India Pharma Fund - Growth has no lock in period.
Fund Manager of Nippon India Pharma Fund - Growth, since 25 May 2018
Fund Manager of Nippon India Pharma Fund - Growth, since 1 April 2005
5Y CAGR
▲ 34.09
5Y CAGR
▲ 34.04
5Y CAGR
▲ 38.81
5Y CAGR
▲ 33.39
3Y CAGR
▲ 29.66